<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37400575</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>03</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Higher CD4<sup>+</sup>CD40<sup>+</sup>&#x2009;T cells (Th40 cells) associate with systemic lupus erythematosus activity.</ArticleTitle><Pagination><StartPage>10702</StartPage><MedlinePgn>10702</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">10702</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-023-37749-y</ELocationID><Abstract><AbstractText>The aim of this study was to investigate the characteristics of CD4<sup>+</sup>CD40<sup>+</sup>&#x2009;T cells (Th40 cells) in Chinese systemic lupus erythematosus (SLE) patients. Flow cytometry was used to identify the percentage of Th40 cells in peripheral blood from 24 SLE patients and 24 healthy individuals and the level of IL-2, IL-4, IL-6, IL-10, IFN-r, and TNF-&#x3b1; in serum (22 cases) from the SLE patients. Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2000) was used to assess the SLE disease active state. The percentage of Th40 cells in T cells from SLE patients (19.37&#x2009;&#xb1;&#x2009;17.43) (%) was significantly higher than that from healthy individuals (4.52&#x2009;&#xb1;&#x2009;3.16) (%) (P&#x2009;&lt;&#x2009;0.001). The percentage of Th40 cells was also positively associated with SLEDAI-2000 (P&#x2009;=&#x2009;0.001) and negatively associated with complement C3 (P&#x2009;=&#x2009;0.007). The Th40 cell percentage was different in SLE patients with different organs involved. The Th40 cell percentage in SLE patients with lupus serositis (29.29&#x2009;&#xb1;&#x2009;22.19) was significantly higher than that in patients without serositis (13.41&#x2009;&#xb1;&#x2009;10.79; P&#x2009;=&#x2009;0.040), and the percentage in SLE patients with lupus pneumonia involvement (29.11&#x2009;&#xb1;&#x2009;11.88) was significantly higher than that in patients without lupus pneumonia (16.80&#x2009;&#xb1;&#x2009;17.99; P&#x2009;=&#x2009;0.043). After 4&#xa0;weeks treatment, the Th40 cell percentage decreased significantly (P&#x2009;=&#x2009;0.005). However, Th40 cell expression was not related to cytokines (IL-2, IL-4, IL-6, IL-10, IFN-r, and TNF-&#x3b1;; P&#x2009;&gt;&#x2009;0.05). A significantly higher percentage of Th40 cells was found in SLE patients, and the Th40 cell percentage was associated with SLE activity. Thus, Th40 cells may be used as a predictor for SLE disease activity and severity and therapeutic efficacy.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhu</LastName><ForeName>Lihua</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, First Affiliated Hospital, Jinan University, Guangzhou, 510632, China. zhulihua20121113@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Hematology, School of Medicine, Jinan University, Guangzhou, 510632, China. zhulihua20121113@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Song</LastName><ForeName>Guangmei</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, First Affiliated Hospital, Jinan University, Guangzhou, 510632, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chen</LastName><ForeName>Xiaohui</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Hematology, School of Medicine, Jinan University, Guangzhou, 510632, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Hematology, School of Medicine, Jinan University, Guangzhou, 510632, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Yanjie</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, First Affiliated Hospital, Jinan University, Guangzhou, 510632, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiao</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, First Affiliated Hospital, Jinan University, Guangzhou, 510632, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Xinran</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, First Affiliated Hospital, Jinan University, Guangzhou, 510632, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xueqin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Hematology, School of Medicine, Jinan University, Guangzhou, 510632, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiaoen</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Hematology, School of Medicine, Jinan University, Guangzhou, 510632, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Xiangbo</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Hematology, School of Medicine, Jinan University, Guangzhou, 510632, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yangqiu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Hematology, School of Medicine, Jinan University, Guangzhou, 510632, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Liang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Oncology, First Affiliated Hospital, Jinan University, Guangzhou, 510632, China. wangliang@jnu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Hematology, School of Medicine, Jinan University, Guangzhou, 510632, China. jnlibo517@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>130068-27-8</RegistryNumber><NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>207137-56-2</RegistryNumber><NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016753" MajorTopicYN="N">Interleukin-10</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015847" MajorTopicYN="N">Interleukin-4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012700" MajorTopicYN="Y">Serositis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011014" MajorTopicYN="Y">Pneumonia</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>4</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>3</Day><Hour>23</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37400575</ArticleId><ArticleId IdType="pmc">PMC10317960</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-37749-y</ArticleId><ArticleId IdType="pii">10.1038/s41598-023-37749-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Herrada AA, et al. Innate immune cells' contribution to systemic lupus erythematosus. Front. Immunol. 2019;10:772. doi: 10.3389/fimmu.2019.00772.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00772</ArticleId><ArticleId IdType="pmc">PMC6476281</ArticleId><ArticleId IdType="pubmed">31037070</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Q, et al. Integrative analysis of long non-coding RNAs and messenger RNA expression profiles in systemic lupus erythematosus. Mol. Med. Rep. 2018;17:3489&#x2013;3496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5802165</ArticleId><ArticleId IdType="pubmed">29286106</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang HT, Chen JM, Guo J, Lan Y, Wei YS. The association of interleukin-31 polymorphisms with interleukin-31 serum levels and risk of systemic lupus erythematosus. Rheumatol. Int. 2016;36:799&#x2013;805. doi: 10.1007/s00296-016-3422-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-016-3422-6</ArticleId><ArticleId IdType="pubmed">26769434</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, et al. Identification of key biomarkers and immune infiltration in systemic lupus erythematosus by integrated bioinformatics analysis. J. Transl. Med. 2021;19:35. doi: 10.1186/s12967-020-02698-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-020-02698-x</ArticleId><ArticleId IdType="pmc">PMC7814551</ArticleId><ArticleId IdType="pubmed">33468161</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwitz DA. Regulatory T cells in systemic lupus erythematosus: Past, present and future. Arthritis Res. Ther. 2008;10:227. doi: 10.1186/ar2511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar2511</ArticleId><ArticleId IdType="pmc">PMC2656253</ArticleId><ArticleId IdType="pubmed">19040771</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwitz DA. Peripheral blood CD4+ T cells in systemic lupus erythematosus. Lupus. 2001;10:319&#x2013;320. doi: 10.1191/096120301676469109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120301676469109</ArticleId><ArticleId IdType="pubmed">11403261</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaitaitis GM, Olmstead MH, Waid DM, Carter JR, Wagner DH., Jr A CD40-targeted peptide controls and reverses type 1 diabetes in NOD mice. Diabetologia. 2014;57:2366&#x2013;2373. doi: 10.1007/s00125-014-3342-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-014-3342-5</ArticleId><ArticleId IdType="pmc">PMC4183717</ArticleId><ArticleId IdType="pubmed">25104468</ArticleId></ArticleIdList></Reference><Reference><Citation>Waid DM, Vaitaitis GM, Wagner DH., Jr Peripheral CD4loCD40+ auto-aggressive T cell expansion during insulin-dependent diabetes mellitus. Eur. J. Immunol. 2004;34:1488&#x2013;1497. doi: 10.1002/eji.200324703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.200324703</ArticleId><ArticleId IdType="pubmed">15114683</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner DH, Jr, Newell E, Sanderson RJ, Freed JH, Newell MK. Increased expression of CD40 on thymocytes and peripheral T cells in autoimmunity: A mechanism for acquiring changes in the peripheral T cell receptor repertoire. Int. J. Mol. Med. 1999;4:231&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">10425271</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner DH, Jr, et al. Expression of CD40 identifies a unique pathogenic T cell population in type 1 diabetes. Proc. Natl. Acad. Sci. USA. 2002;99:3782&#x2013;3787. doi: 10.1073/pnas.052247099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.052247099</ArticleId><ArticleId IdType="pmc">PMC122601</ArticleId><ArticleId IdType="pubmed">11891296</ArticleId></ArticleIdList></Reference><Reference><Citation>Waid DM, Vaitaitis GM, Pennock ND, Wagner DH., Jr Disruption of the homeostatic balance between autoaggressive (CD4+CD40+) and regulatory (CD4+CD25+FoxP3+) T cells promotes diabetes. J. Leukoc. Biol. 2008;84:431&#x2013;439. doi: 10.1189/jlb.1207857.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.1207857</ArticleId><ArticleId IdType="pmc">PMC2493071</ArticleId><ArticleId IdType="pubmed">18469093</ArticleId></ArticleIdList></Reference><Reference><Citation>Waid DM, et al. A unique T cell subset described as CD4loCD40+ T cells (TCD40) in human type 1 diabetes. Clin. Immunol. 2007;124:138&#x2013;148. doi: 10.1016/j.clim.2007.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2007.05.003</ArticleId><ArticleId IdType="pubmed">17560173</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaitaitis GM, Yussman MG, Waid DM, Wagner DH., Jr Th40 cells (CD4+CD40+ Tcells) drive a more severe form of Experimental Autoimmune Encephalomyelitis than conventional CD4 T cells. PLoS&#xa0;One. 2017;12:e0172037. doi: 10.1371/journal.pone.0172037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0172037</ArticleId><ArticleId IdType="pmc">PMC5305068</ArticleId><ArticleId IdType="pubmed">28192476</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter J, Vaitaitis GM, Waid DM, Wagner DH., Jr CD40 engagement of CD4+ CD40+ T cells in a neo-self antigen disease model ablates CTLA-4 expression and indirectly impacts tolerance. Eur. J. Immunol. 2012;42:424&#x2013;435. doi: 10.1002/eji.201141880.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201141880</ArticleId><ArticleId IdType="pubmed">22105491</ArticleId></ArticleIdList></Reference><Reference><Citation>Waid DM, et al. Defining a new biomarker for the autoimmune component of Multiple Sclerosis: Th40 cells. J. Neuroimmunol. 2014;270:75&#x2013;85. doi: 10.1016/j.jneuroim.2014.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2014.03.009</ArticleId><ArticleId IdType="pmc">PMC4038952</ArticleId><ArticleId IdType="pubmed">24690203</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaitaitis GM, et al. Biomarker discovery in pre-Type 1 Diabetes; Th40 cells as a predictive risk factor. J. Clin. Endocrinol. Metab. 2019;104:4127&#x2013;4142. doi: 10.1210/jc.2019-00364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2019-00364</ArticleId><ArticleId IdType="pmc">PMC6685715</ArticleId><ArticleId IdType="pubmed">31063181</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat. Rev. Immunol. 2018;18:773&#x2013;789. doi: 10.1038/s41577-018-0066-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-018-0066-7</ArticleId><ArticleId IdType="pubmed">30254251</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>